Ucb (UCB.BR) Azione Prezzo
Ucb Prezzo
Negli ultimi 19 anni Ucb ha aumentato il fatturato del 6,1% all'anno, raggiungendo 7,74 miliardi EUR. L'utile per azione è cresciuto del 6,5% all'anno negli ultimi 19 anni. Per Ucb, il margine netto del 20,1% risulta in aumento rispetto al 18,3% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 0,48%. Il payout ratio è pari a circa il 17% degli utili. Il dividendo è cresciuto del 2,4% all'anno negli ultimi 19 anni. Il target di prezzo di consenso a 12 mesi per Ucb è 280,50 EUR, circa il 3,7% sotto il prezzo attuale di mercato. Su 26 analisti, 20 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Ucb Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Ucb Azione e analisi azionaria
Domande frequenti sull'azione Ucb
UCB SA is primarily active in the healthcare and pharmaceutical industries. With a focus on neurology, immunology, and bone health, UCB SA specializes in the research, development, and commercialization of innovative medicines and solutions. As one of the leading companies in the field, UCB SA aims to improve the lives of patients through advancements in therapy and healthcare services.
The main competitors of Ucb SA in the market include pharmaceutical companies such as Pfizer, Novartis, Roche, and Eli Lilly and Company.
The business model of UCB SA revolves around researching, developing, and commercializing innovative medicines and solutions for patients suffering from severe diseases. UCB SA primarily focuses on neurology and immunology, striving to make a meaningful difference in the lives of patients. The company engages in extensive scientific research, collaborations, and partnerships to bring transformative treatment options to market. By combining its expertise in biology and chemistry, UCB SA aims to deliver targeted therapies and enhance patients' overall well-being. UCB SA's commitment to tackling unmet medical needs makes it a leading player in the pharmaceutical industry.
UCB SA, a prominent pharmaceutical company, has a rich history and background. Established in 1928 in Belgium, UCB SA initially focused on industrial chemistry, gradually shifting its focus towards pharmaceuticals. Over the years, UCB SA has become a global biopharmaceutical leader, specializing in neurology and immunology. The company is renowned for its dedication to research and innovation, developing breakthrough treatments for severe diseases such as epilepsy, Parkinson's, and autoimmune disorders. With a commitment to improving patients' lives, UCB SA maintains strong partnerships and invests in cutting-edge advancements. Through its continuous pursuit of excellence, UCB SA consistently delivers innovative solutions, making a positive impact on countless lives worldwide.
UCB SA, a leading global biopharmaceutical company, has achieved several significant milestones over the years. One notable accomplishment is the development and launch of innovative therapies that have contributed to improving the lives of patients worldwide. In recent years, UCB SA has successfully received regulatory approvals for groundbreaking medications, expanding its portfolio across multiple therapeutic areas. Furthermore, the company has forged strategic collaborations and partnerships to enhance its research and development capabilities, aiming to identify novel treatment options for various health conditions. UCB SA's commitment to scientific excellence and patient-centric approach has positioned it as a prominent player in the healthcare industry, driving advancements in medical science and transforming patient care.
UCB SA is primarily present in several countries and regions across the globe. The company has a strong presence in Europe, especially in countries such as Belgium, its home country, as well as France and Germany. Additionally, UCB SA has established a significant presence in other regions including the United States, Canada, and various countries in Latin America. With a diversified global footprint, UCB SA extends its reach to markets in Asia-Pacific, particularly in Japan, China, and South Korea. These strategic geographical locations enhance UCB SA's ability to serve a wide range of patients and healthcare professionals worldwide.
UCB SA represents a strong set of values and a clear corporate philosophy. The company focuses on patient-centricity, innovation, and sustainability. UCB is committed to improving the lives of patients with severe diseases and strives to deliver value through the development of advanced therapies. By embracing open collaboration and putting patients at the center of their activities, UCB fosters a culture of continuous learning and growth. The company's corporate philosophy emphasizes integrity, accountability, and a strong belief in advancing science and healthcare. UCB SA's dedication to its core values is evident in its ongoing pursuit of breakthrough solutions to address unmet medical needs.
Gli analisti fissano attualmente un prezzo obiettivo medio di 275,68 EUR per l’azione Ucb (mediana: 280,50 EUR), pari a -5,4 % rispetto all’ultimo prezzo. Il consenso si basa su 26 giudizi di analisti.
26 analisti valutano attualmente l’azione Ucb: 20 raccomandano l’acquisto, 4 la tenuta e 2 la vendita. Per il 2026 gli analisti si aspettano per Ucb ricavi pari a 9,05 miliardi EUR e un utile per azione di 13,52 EUR.
L’azione Ucb (UCB.BR) è quotata su 9 borse, tra cui: London (0NZT.L), SIX (Zürich) (UCB.SW), Frankfurt (UNC.F), München (UNC.MU), Düsseldorf (UNC.DU), Wien (UCB.VI).
UCB SA is a global biopharmaceutical company focused on creating value for patients with neurological and immunological diseases. The company originated in Belgium and now has offices and subsidiaries in over 40 countries worldwide. UCB specializes in the research and development of innovative drugs and therapies to help people with severe or life-threatening illnesses. The company operates in three business areas: drug development, biologics manufacturing, and marketing of branded products in the fields of neurology and immunology. UCB's core competencies lie in the discovery, development, and commercialization of drugs that contribute to the treatment of neurological and immunological diseases. UCB's flagship products include Cimzia, Vimpat, and Keppra. The company is also known for products such as Zyrtec, an antiallergic, and Nootropil, a cognitive function-enhancing drug. Cimzia is a drug used to treat Crohn's disease and rheumatoid arthritis and has proven to be highly effective. Vimpat and Keppra are medications used for the treatment of epilepsy and, in some cases, neuropathic pain disorders. UCB operates its own research centers as well as partnerships with universities, research labs, and other companies to develop new drugs and advance science and technology. It employs several thousand employees in areas such as research and development, manufacturing, marketing, and sales. In biologics manufacturing, the company specializes in producing antibodies that help strengthen the immune system to fight diseases. UCB's biologics line consists of four products: Cimzia, Romosozumab, Rozanolixizumab, and Bimekizumab. Biologics manufacturing is a complex and highly specialized process that requires quality control and strict regulatory requirements. UCB markets its pharmaceutical products in over 100 countries worldwide. The company's market presence includes products for the treatment of epilepsy, Crohn's disease, rheumatoid arthritis, osteoporosis, and allergic reactions. The company is working to expand its portfolio with new products tailored to the needs of patients with rare or severe diseases in the coming years. Overall, UCB's business model is focused on the development of innovative drugs and therapies to meet the needs of people with neurological and immunological diseases. The company engages in research and development, manufacturing, and distribution of medications and biologics in a variety of areas. UCB takes pride in offering high-quality and innovative treatment options to patients and their medical professionals to improve their health and quality of life.
Il attesa fatturato di Ucb ammonta a 9,05 miliardi EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Ucb ammonta a 2,57 miliardi EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Ucb è attualmente 21,54. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Ucb.
Il rapporto prezzo/fatturato (P/S) di Ucb è attualmente 6,11. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Ucb.
Il Quality Score AlleAktien per Ucb è 7/10.
L'ISIN di Ucb è BE0003739530. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Ucb è 852738. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Ucb è UCB.BR. Con questo simbolo di borsa vengono negoziate le azioni Ucb in borsa.
Azione Ucb
Gruppo di pari di Ucb
Ucb Ticker
Ucb FIGI
Altre metriche e analisi di Ucb in Deep Dive.
La nostra analisi azionaria dell'azione Ucb include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Ucb. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: